Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) closed at $42.31 in the last session, up 0.17% from day before closing price of $42.24. In other words, the price has increased by $0.17 from its previous closing price. On the day, 1.15 million shares were traded. CERE stock price reached its highest trading level at $42.46 during the session, while it also had its lowest trading level at $41.995.
Ratios:
We take a closer look at CERE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 10.22 and its Current Ratio is at 10.22. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.85.
On September 28, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $33.Piper Sandler initiated its Overweight rating on September 28, 2023, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 10 ’24 when COLES N ANTHONY sold 50,000 shares for $42.10 per share. The transaction valued at 2,105,125 led to the insider holds 15,638 shares of the business.
COLES N ANTHONY sold 50,000 shares of CERE for $2,116,640 on Apr 01 ’24. The Director now owns 15,638 shares after completing the transaction at $42.33 per share. On Mar 04 ’24, another insider, COLES N ANTHONY, who serves as the Director of the company, sold 50,000 shares for $41.01 each. As a result, the insider received 2,050,550 and left with 15,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CERE now has a Market Capitalization of 7708670976 and an Enterprise Value of 7344663552.
Stock Price History:
The Beta on a monthly basis for CERE is 1.44, which has changed by 0.3238423 over the last 52 weeks, in comparison to a change of 0.2644323 over the same period for the S&P500. Over the past 52 weeks, CERE has reached a high of $43.59, while it has fallen to a 52-week low of $19.59. The 50-Day Moving Average of the stock is 0.44%, while the 200-Day Moving Average is calculated to be 25.85%.
Shares Statistics:
According to the various share statistics, CERE traded on average about 1.31M shares per day over the past 3-months and 940750 shares per day over the past 10 days. A total of 181.36M shares are outstanding, with a floating share count of 87.29M. Insiders hold about 52.09% of the company’s shares, while institutions hold 44.99% stake in the company. Shares short for CERE as of 1714435200 were 6599441 with a Short Ratio of 5.05, compared to 1711584000 on 9622787. Therefore, it implies a Short% of Shares Outstanding of 6599441 and a Short% of Float of 7.59.
Earnings Estimates
Cerevel Therapeutics Holdings Inc (CERE) is currently under the scrutiny of 7.0 analysts, each contributing to the ongoing evaluation of its stock.On average, analysts expect EPS of -$0.61 for the current quarter, with a high estimate of -$0.49 and a low estimate of -$0.76, while EPS last year was -$0.67. The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.38 and low estimates of -$0.8.
Analysts are recommending an EPS of between -$1.4 and -$3.25 for the fiscal current year, implying an average EPS of -$2.55. EPS for the following year is -$2.88, with 8.0 analysts recommending between -$2.18 and -$3.3.
